Observations regarding the immunogenicity of BDD-rFVIII derived from a mechanistic personalized medicine perspective
- Z. E. Sauna,
- ,
- B. Kim,
- C. Yanover,
- K. R. Viel,
- R. Rajalingam
- United States Food and Drug Administration,
- ,
- University of California at San Francisco,
- Fred Hutchinson Cancer Research Center,
- Histonis,
- University of California at Los Angeles
Scholary Output:
Contribution to journal
Letter
Peer-review
Open access
Publication Information
Output type
Scholary Output:
Contribution to journal
Letter
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 1961-1965 (5 pages)Journal (Volume, Issue Number)
Journal of Thrombosis and Haemostasis (Volume 10, Issue 9)Publication milestones
- Published - 09/2012
Publication status
Published - 09/2012
ISSN
1538-7933Publication IDs
- Scopus: 84865790103
- PubMed: 22734827
Publication metrics
Metrics
Fractional count
1
Fractional count
0.13
Fractional count
7
Fractional count
0.88
Fractional count
1
Fractional count
1
SciVal
FWCI
1.59
SciVal
Author count
8
SciVal
citations
7
SciVal
Paper percentile
59
PlumX, opens in new tab
Captures
10
Citation count
8
Funding Details
The authors would also like to thank V. La Terza, C. Kasper and J. Lusher for helpful discussions and technical editing during the preparation of this manuscript. Research conducted in the laboratory of ZES is funded by the modernization of science program of the Center for Biologics Evaluation and Research, Food and Drug Administration. Research conducted in the laboratory of TEH is funded by grants from the National Heart, Lung, and Blood Institute of the National Institutes of Health (1RC2‐HL101851, HL‐71130 and HL‐72533) as well as from the: Bayer Healthcare Corporation, Bayer Hemophilia Awards Program and Baxter Healthcare Corporation.
FunderFunding number
NHLBI
RC2HL101851